STOCK TITAN

Immutep - IMMP STOCK NEWS

Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.

Overview of Immutep Ltd

Immutep Ltd is a globally active biotechnology company committed to advancing immunotherapy for both cancer and autoimmune diseases. Leveraging its expertise in immuno-oncology and innovative LAG-3 technology, the company has positioned itself as a specialized entity in personalized bio-therapeutic products. With dual listings on the Australian Stock Exchange and Nasdaq, Immutep demonstrates a robust international presence and a solid foundation in research and development.

Core Technology and Therapeutic Approach

The hallmark of Immutep’s approach is its focus on the LAG-3 immune control mechanism, a critical regulator of the T cell immune response. By modulating this pathway, Immutep aims to enhance the body’s natural ability to fight cancer and potentially address autoimmune conditions. This technology underpins the company’s strategic pipeline and sets a high standard for clinical precision and targeted therapy development.

Product Pipeline and Clinical Development

Immutep’s product portfolio is centered around its most advanced candidate, IMP321, which functions as a T cell immunostimulatory factor. This therapy is designed for integration into cancer chemoimmunotherapy protocols and has achieved significant clinical milestones in early phase trials. In addition to IMP321, the company is developing IMP701, a blocking anti-LAG-3 antibody candidate in early clinical evaluation, and CVac, a personalized immunocellular strategy under investigation for epithelial cancers. These development efforts illustrate a diverse and forward-looking approach that integrates both innovation and strategic collaboration.

Global Operations and Strategic Collaborations

Operating primarily from Australia, Immutep extends its influence across global markets, supported by strong regulatory compliance and research proficiency. Strategic partnerships with large pharmaceutical firms reinforce its pipeline development, enabling access to advanced clinical platforms and shared expertise. The company’s qualification for significant research tax incentives in both Europe and Australia underscores its commitment to high-caliber R&D and validates the commercial and scientific merits of its initiatives.

Industry Position and Business Model

Within the competitive landscape of biotechnology, Immutep differentiates itself by combining deep scientific expertise with a focused therapeutic strategy. Its business model hinges on collaborative partnerships, clinical innovation, and a targeted approach to harnessing LAG-3 mediated immune modulation. Investors and industry observers appreciate the rigorous clinical frameworks employed by the company, which underpin its potential to offer novel therapeutic modalities in the area of cancer treatment and beyond.

Research and Development Excellence

Immutep’s strategic emphasis on research and development is reflected in its participation in international R&D incentive programs. These initiatives not only provide substantial financial support for its clinical trials but also affirm the company’s adherence to high industry standards and scientific integrity. This relentless focus on innovation is at the core of Immutep’s operational ethos, ensuring that its immunotherapeutic solutions are developed in a rigorous and transparent environment.

Conclusion

In summary, Immutep Ltd stands as a key player in the biotechnology industry, with a specific focus on immunotherapy modalities for cancer and autoimmune diseases. Its reliance on advanced LAG-3 technology, comprehensive product pipeline, and robust global partnerships collectively fortify its standing in the competitive landscape. The company’s commitment to R&D excellence and transparent clinical strategies provides a rich source of insight for those seeking to understand a pioneering approach in modern biotechnology.

Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The company also received an A$1.13 million cash rebate from the Australian Federal Government’s R&D tax incentive program. The funds will be used to support the ongoing and planned global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
Rhea-AI Summary
Immutep Limited (IMM) announces the expansion of the INSIGHT-003 trial to four sites in Germany, supporting faster enrolment in the study evaluating eftilagimod alpha in combination with KEYTRUDA and doublet chemotherapy for NSCLC. The trial is expected to complete recruitment in 1H CY2024, with promising early clinical data showing a 70.6% overall response rate and 10.9-month median progression-free survival in patients with PD-L1 TPS of <50%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
-
Rhea-AI Summary
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the completion of patient enrollment in the TACTI-003 Phase IIb trial evaluating efti in combination with pembrolizumab for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The trial enrolled 171 patients in the US, Europe, and Australia, with the primary endpoint being Overall Response Rate. Results are expected in H1 CY2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
Rhea-AI Summary
Immutep Limited announces the completion of the open-label safety lead-in phase of its AIPAC-003 Phase II/III trial. The trial evaluated the combination of 90mg eftilagimod alpha (efti) with paclitaxel in six patients with metastatic breast cancer. There were no safety or tolerability issues, and the independent Data Monitoring Committee recommended proceeding to the randomized Phase II portion of the trial. The Phase II portion will include up to 58 evaluable patients to determine the optimal biological dose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Immutep Limited announces new biomarker data from the TACTI-002/KEYNOTE-798 Phase II trial, showing statistically significant increases in Th1 biomarkers and immune activating genes. The data supports the success of eftilagimod alpha (efti) in first-line treatment of non-small cell lung cancer (NSCLC) patients. The increase in absolute lymphocyte count (ALC) is correlated with positive overall survival results. Similar immune response biomarkers were seen in the AIPAC Phase IIb trial in metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
-
Rhea-AI Summary
Immutep Limited announces its management's participation in upcoming investor events in November. The events include Baird's Biotech Discovery Series and Jefferies London Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
conferences
Rhea-AI Summary
Immutep Limited provides an update on the development of its product candidates, including positive survival results in the TACTI-002 trial for non-small cell lung cancer (NSCLC). The trial showed a median Overall Survival of 35.5 months, providing an additional 12-18 months compared to historical data. The company is also progressing in other trials for head and neck squamous cell carcinoma (HNSCC) and metastatic breast cancer (MBC). Immutep has a strong cash position of $110.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
Rhea-AI Summary
Immutep Limited has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The rebate is for eligible R&D activities conducted in the 2022 fiscal year, specifically related to the TACTI-002 and TACTI-003 clinical studies using its lead compound eftilagimod alpha. Immutep will use the funding to further its current active clinical trial programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.66%
Tags
none
-
Rhea-AI Summary
Immutep reports promising clinical data from the INSIGHT-003 trial evaluating a triple combination therapy for metastatic non-small cell lung cancer. The therapy showed strong efficacy with a 71.4% Overall Response Rate, 90.5% Disease Control Rate, and a median Progression Free Survival of 10.1 months. The combination also demonstrated positive results in patients with low or negative PD-L1 expression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.39%
Tags
Rhea-AI Summary
Immutep Limited announces excellent new clinical data from the TACTI-002 / KEYNOTE-798 Phase II trial evaluating eftilagimod alpha in combination with KEYTRUDA for the treatment of non-small cell lung cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
none

FAQ

What is the current stock price of Immutep (IMMP)?

The current stock price of Immutep (IMMP) is $1.77 as of April 1, 2025.

What is the market cap of Immutep (IMMP)?

The market cap of Immutep (IMMP) is approximately 260.6M.

What is the core focus of Immutep Ltd?

Immutep primarily focuses on developing immunotherapy products for cancer and autoimmune diseases, leveraging the unique LAG-3 immune mechanism to modulate T cell responses.

How does Immutep utilize LAG-3 technology in its treatments?

The company harnesses LAG-3 technology to regulate the activity of T cells, enabling enhanced immune responses against cancer cells while potentially addressing autoimmune conditions through precise immunomodulation.

What are the key products in Immutep’s development pipeline?

Immutep’s pipeline includes IMP321, a T cell immunostimulatory factor, along with candidates like IMP701 and CVac, which are being developed to address various cancer indications within rigorous clinical settings.

In what ways does Immutep engage in global operations?

While headquartered and predominantly operating from Australia, Immutep maintains a global presence via dual market listings and strategic R&D initiatives, supported by international collaborations and tax incentive programs.

How do Immutep’s strategic partnerships influence its business model?

The company collaborates with major pharmaceutical partners, which enhances its clinical development capabilities, expands its market reach, and reinforces its innovative approach in the competitive biotechnology sector.

What role do research tax incentives play in Immutep’s operations?

Immutep benefits from research tax incentives in both Europe and Australia, which support its R&D expenditures. These incentives validate the company’s commitment to scientific excellence and reinforce its robust clinical development initiatives.

How does Immutep maintain its expertise and trustworthiness in the biotech industry?

Through a strategic focus on advanced immunotherapeutic solutions, adherence to rigorous clinical trial standards, and transparent communication of its scientific and business practices, Immutep demonstrates deep industry expertise and commitment to research integrity.
Immutep

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

260.55M
145.44M
0.01%
2.06%
3.46%
Biotechnology
Healthcare
Link
Australia
Sydney